Peter

@Riccardino999 excellent margins, though and low fixed costs probably too good a business for a short?

Resistance around the 20,000 mark To me this looks like a potential short

#gaw #gamesworkshop Trading update should come out in the next few days Remember this is trading at 10x sales and the economy is softening If the update disappoints the first bid you will catch will be between -30 and -50% And if it doesn't you are looking at a +5-7% with

@A_May_MD @DominickCampag Just let it compound a few hundred years and you’re all set.

@DominickCampag You’re referring to a 5% gain in 10 years $XBI

We are going back to this if rates don’t start to cooperate at least a little btw

@MoodyWriter13 Thanks, very interesting landscape analysis. Since, you mentioned POET, do you regard them as a serious company?

Earlier this morning, I shared my thoughts on Substack about bottlenecks in general, and specifically about InP and $SIVE. Based on the feedback, the article was well received. If you’re interested, you can find it directly here These are just my thoughts, and I don’t claim to be always right. open.substack.com/pub/fwriter/p/…

@AppleHelix Well, BMS might have taken the right decision, who knows. That’s part of what makes business and politics so exciting: the counter factual doesn’t exist. It could be that both BMS and MRK chose wisely. Do you know why it wasn’t an option for BMS to simply start both trials?

This is pretty cool experiment. Don’t trust AI to make clinical trial decision yet

@CuiBonoCapital @RNAiAnalyst Well, Dirk referenced a tweet that said: “FDA should be about safety, the physicians and ultimately the markets decide what's efficient.”, which is a stupid statement. I just don’t like witch hunts, that’s all.

@Loving_pharma @RNAiAnalyst It isn’t. And no one is suggesting or has suggested otherwise. This is AV’s attempt as obfuscation. Make a statement that everyone, everywhere agrees with so as to come across as reasonable despite it being unrelated to the idiosyncratic issue at hand.

Ex-Enron trader John Arnold admits to having bought his way into FDA decision making.

@seedy19tron @kennethon11 @thegresearch

@kennethon11 @thegresearch Short answer +ive correlation

Read this one if you read nothing else from me. You're on one of three paths right now. You cannot afford to be on the wrong one.

@mgzxbt @Merridew__ Well, if there is a high cost of changing the provider there is less pressure on revenues to follow costs.

@Loving_pharma @Merridew__ Why does that matter that these services will be a race to the bottom over time?

@Biotech2k1 Why not ROOT?

If $LIFE traded at same valuatuon on P/S as $LMND, it would be $50.

@AppleHelix While their software is good, I think you’re vastly overestimating the competitive advantage they have. In the end it’s a tool like others. Just think of all the drugs that were designed using Bruker’s NMRs. Did Bruker get a cut of the profits 😀

Quite the contrast between companies that were sold based on small molecules designed by $SDGR (e.g., Nimbus, Morphic, and now Ajax) and its stock performance. Must be frustrating for shareholders. What is wrong with the business model??

@bradloncar @US_FDA @Replimune Thanks, Brad. Your interviews are really helpful.

Some observers, including @US_FDA, have criticized @Replimune for the design of the trial that led to the decision not to grant accelerated approval of their melanoma treatment. I asked the company's Chairman about that view. Watch the full interview: biotechtv.com/post/replimune…

@bradloncar @WassimLaroussi3 What’s his explanation for the differences between the FDA’s and their version of what had been agreed upon between the parties?

Later today, I'm going over to Replimune to speak with their Chairman about all that's happened. Let me know any questions you'd like me to ask. Scheduled to record at noon and it will be up later in the afternoon.

@yzhu2 @seedy19tron Without that dump the price would have been higher. Someone saved themselves some money.

@seedy19tron Read between the line. The financing deal is based on the closing price yesterday. It could have been $7

$anl some top names in the pipe , insane opportunity yesterday to add

@AnotherBio @Lord_of_Biotech UK stocks are doomed to wither and wither till they’re bought out for a pittance or simply die of neglect.

A certain idiot with 0 scientific credentials whatsover thinks that the $PRTC Seaport stake is now worth more than its entire market cap

@DeepSailCapital Yeah, feels like the enthusiasm is broken and still a lot of room to fall.

One strategy I like to use is just short more $OKLO and $QUBT everyday.

@MysteriousMole1 It’s amazing watching crimes committed in broad daylight. I once had a saviour complex and tried to help the followers of one such scheme but found out that they don’t want to be helped. I now simply try to profit on the “dump” side.

@plainyogurt21 Not a QURE advocate, but for any disease with a clearly established disease progression NH should be sufficient w/ length and N dependent on observed variability. I wouldn’t argue that placebo arms in these diseases are unethical per se, though.

For the $QURE advocates, do we think PTC and Skyhawk should be approved using non placebo controlled data and their current phase 3 trials are unethical?

@EricJhonsa Congrats! Wishing you great success in your new role. Turbulent waters will make for good fishing.

Some personal news: I’ve accepted a position as a portfolio manager for Dutch Asset Corporation, an RIA that provides actively-managed portfolios (primarily featuring individual stocks) for high-net-worth clients and institutions. At Dutch, I’ll be managing money using a diversified, tech-focused, long-short equity approach similar to the one I've been applying on my own over the last few years. I’ve been providing consulting services for Dutch since 2023 and have gotten to know the firm’s founder, Cullen Breen, well over that time. After meeting with Cullen and other Dutch team members in October, and passing the Series 65 exam in December, I agreed to join the firm as a PM. Agreeing to manage outside money isn’t something I did lightly, both due to the responsibilities involved and because I’ve enjoyed what I’ve been doing over the last few years. But I’m looking forward to the challenge of applying my strategy on a larger scale, and to having the additional resources that a firm like Dutch can provide. To avoid conflicts of interest, the only personal funds I’ll be trading stocks with will be among the assets that I’ll be collectively managing at Dutch. And for compliance reasons, I won’t be able to share portfolio holdings or returns on here going forward. But I’ll continue sharing thoughts on markets, companies, and tech trends over here. (Boilerplate disclaimer: Dutch Asset Corporation is a registered investment adviser. Any prior investment activity shared was not in a professional capacity and is not indicative of future results. Full disclosures: dutchasset.com/disclosures)

@xairsman @adamfeuerstein Don't want to rehash the debate. What everyone should be able to agree upon is that the FDA did an extraordinarily bad job in explaining their new decision standards. Public pronouncements seemed to run counter to actual decisions, and the public did not understand the rationale.

@Loving_pharma @adamfeuerstein The FDA came up with Fake Brain Surgeries to test AMT-130 against those who got the drug. Is that the best we can do?

Let's look at how the FDA is treating $SRPT and $QURE differently. The FDA grants accelerated approval to Amondys and Vyondys to treat Duchenne muscular dystrophy. Sarepta conducts a post-marketing confirmatory study that fails to show a benefit for either drug. There is no evidence that patients are benefiting from either drug, based the outcome of a randomized, controlled study. Still, Sarepta pushes forward, seeking to convert accelerated approval to final approval. The FDA allows Sarepta to submit an application. "The adequacy of the data to support conversion to traditional approval will be a matter of review," the FDA concludes, according to Sarepta. Amondys and Vyondys should be withdrawn from the market. My opinion. I've said that repeatedly. There's a process, of course, so FDA should review the data. That's what regulators are supposed to do. And then, there's UniQure and AMT-130, its treatment for Huntington's disease.... The FDA won't even allow UniQure to submit an application for accelerated approval. Bar the door, the FDA says, not even a review. investorrelations.sarepta.com/news-releases/…